-
XtalPi Partners with Parthenon Therapeutics to Harness AI for Solid Tumor Antibody Development
•
Sino-US artificial intelligence (AI) firm XtalPi Inc. has entered into a strategic partnership with US cancer therapy developer Parthenon Therapeutics Inc. to develop antibodies targeting solid tumors. This collaboration aims to leverage the power of AI to advance oncology treatments. Access to XtalPi’s XupremAb Platform and “Experiment+AI” SolutionsUnder the terms…
